10x Genomics forecasts $625M-$635M 2026 revenue as it targets ~50 Atera shipments by year-end (NASDAQ:TXG)
10x Genomics (TXG) reported Q3 2026 revenue of $151M, up 1% YoY. The company forecasts 2026 revenue of $625M-$635M, targeting ~50 Atera shipments by year-end, according to CEO Serge Saxonov.
How this was made
The 30-second read
Why it matters
The disclosed guidance provides the first concrete FY2026 revenue range, which can shift market expectations and affect the stock price.
Market read
New guidance is a primary catalyst for TXG and may influence peer valuations in the genomics sector.
What to watch
Potential revenue upside from accelerated Atera adoption or new product launches not reflected in the current guidance.
Background
The article is an AI‑generated earnings call summary from Seeking Alpha, presenting the latest quarterly numbers and forward outlook.
Ticker impact
10x Genomics disclosed Q3 revenue of $151M and forecast FY2026 revenue of $625M‑$635M, marking the first public guidance release.
potential downside as guidance is modest relative to prior expectations
First‑time disclosure of full‑year guidance provides fresh data that traders can price in immediately.
Market effects
Guidance may affect other genomics and biotech firms as investors compare growth expectations.
Primarily U.S. market impact; limited regional effect.
Low global relevance beyond the biotech sector.
Counterpoint
If investors view the guidance as a floor rather than a ceiling, the stock could rally on perceived upside potential.
Key entities
- company10x Genomics
US‑listed genomics technology firm (NASDAQ:TXG).
